FIELD: medicine.
SUBSTANCE: invention relates to the use of a compound of 1-(2-(1-methylimidazole-4-yl)ethyl)piperidine-2,6-dione of the formula (I) or its pharmaceutically acceptable salt, hydrate or solvate for the manufacture of a pharmaceutical composition for the prevention and/or treatment of COVID-19, as well as to a method for the prevention and/or treatment of COVID-19, including the administration to a subject who needs it of the pharmaceutical composition containing from 0.01 to 99.99 wt.%.
EFFECT: treatment of COVID-19.
(I)
3 cl, 1 dwg, 3 tbl, 1 ex
Authors
Dates
2022-06-27—Published
2020-06-26—Filed